Boundless Bio gets FDA clearance for cancer drug trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to Boundless Bio gets FDA clearance for cancer drug trial

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

January 20, 2026 7:00 AM EST

BBI-940 IND accepted; initiation of first-in-human clinical trial on track 
for the first half of 2026

Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second half of 2028

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative... More